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Abstract
In this paper, old as well as new technological findings to decrease premature infant mortality are
reviewed. This paper discusses fetal development throughout pregnancy from conception to fullterm status as well as fetal lung development specifically from conception until full-term status.
Several ideas to rapidly develop and mature fetal lungs are discussed such as mothers ingesting
artificial surfactant supplements, either independently or coupled with antenatal corticosteroids,
as well as intra-amniotic instillation prior to 28 weeks gestational. Drawbacks regarding these
two are mentioned as well such as the fetus’s lungs not being mature enough to use the artificial
surfactant leading into the idea of researching ways to rapidly develop fetal lungs, either weekby-week or stage-by-stage. Lastly, if the baby is born pre-maturely and is severely
underdeveloped, research is currently being done on an artificial womb that the baby can be
placed in to simulate a uterus where the fetus can develop on a normal timeline as he or she
would in the mother’s womb.
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Introduction
Babies are the future of the world, but is the healthcare system doing all they can do to
ensure these babies have the best future ahead of them? What about premature babies? While
premature babies get extra attention due to being born before their gestational maturation stage,
what can be done to possibly prevent premature birth or at least ensure a faster recovery time for
this new infant so they do not have to spend the first few months in the Neonatal Intensive Care
Unit, or NICU? This is not only a difficult road for the infant as they are connected to lifesustaining machines for weeks, but it also presents an also an enormous stress on the infant’s
family. Newborns crave the touch, smell, and bonding time with their parents, but the parents
also crave this for their newborn baby. Being without this intimate bonding moment can often
lead to stress for both parties, as along with delayed mental and physical development early-on
as well as later in life (Flacking et al, 2012). With this being said, how can the healthcare system
ensure premature babies are supported and healthy enough at the time of their birth to decrease
their overall stay in the NICU after their birth? Furthermore, how can mortality rate be decreased
among babies born prematurely, specifically at 24 weeks or younger? Technology is always
evolving and could be a significant benefactor in detecting, as well as accelerating lung
development in utero to result in a shorter hospital stay after a premature birth. This thesis will
attempt to provide a greater insight into technologies currently being used to aid in these
situations, and how can they be improved for better, quicker results.
Background
A fetus is considered to be full term at 39 weeks gestational (Know Your Terms, 2019).
However, fetuses, or babies, are not always so compliant to this rule. Some babies want to meet
their parents sooner, but this sooner-than-expected visit comes with a price. Babies are not
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considered “viable” until they are about 24 weeks gestational (When Is It Safe to Deliver Your
Baby, n.d.). In fact, babies born before 24 weeks usually have less than a 50 percent chance of
survival (When Is It Safe to Deliver Your Baby, n.d.). As weeks go on, the fetus matures more
and more, and survival rates continue to rise as well. One of the most imperative elements of life
is the act of breathing. This can be very difficult for babies who are born pre-term, as their lungs
do not fully develop enough to work independently until later in the gestational phase. In fact, at
birth, the lungs are still not fully developed; they continue to grow until 20 to 23 years of age
(Hill, 2020). Table 1 provides a more in depth view of typical fetal development week to week
until birth.
Fetal Development by Week
Weeks 1 & 2
Week 3
Week 4
Week 5
Week 6
1st
Trimester

Week 7
Week 8
Week 9
Week 10
Week 11
Week 12
Week 13

2nd
Trimester

Week 14
Week 15
Week 16

Getting Ready - Surprise! You are not actually pregnant during this time.
Fertilization - The sperm and egg unite to form a zygote.
Implantation - The zygote travels down to the uterus and begins dividing into a cluster
of cells, called a blastocyte, and burrows into the uterine lining, or endometrium.
Hormone Levels Increase - Human chorionic gonadotropin, or HCG, levels are
increased, and the embryo is now made of 3 layers.
Neural Tube Closes - The neural tube that runs along the baby's back is closing, the
heart begins to form and beat, other organs also begin to form, and the arms begin to
sprout.
Baby's Head Develops - The baby's brain and face begin to take shape and grow, and
the legs begin to sprout.
Baby's Nose Forms - During this week, the baby actually begins to look like a baby as
its facial features begin to form. Its fingers are also growing!
Baby's Toes Appear - The baby's arms are growing, the elbows have formed. The
baby's toes are now visible. The head is large, but the chin is still underdeveloped.
Baby's Elbows Bend - The baby's head becomes more round, its elbows, fingers, and
toes begin to wiggle, and the umbilical cord is clearly visible.
Baby's Genitals Develop - The baby is officially described as a fetus! The body begins
to grow longer, and the genitals begin to form to identify the baby's sex.
Baby's Fingernails Form - The baby's fingernails begin to grow, he or she has a more
developed facial profile, and the intestines of the baby are in the abdomen.
Urine Forms - The baby begins to form urine and expel it into the amniotic fluid. The
baby's bones are beginning to harden, especially the skull and long bones.
Baby's Sex Becomes Apparent - You may now be able to tell your baby's sex, but don't
worry if you can't. It will become more apparent in the following weeks. The baby is
forming red blood cells in the spleen.
Baby's Scalp Pattern Develops - The baby is growing rapidly. The baby's hair pattern is
developing, and his or her bones are continuing to develop.
Baby's Eyes Move - The ears have almost completely formed, the eyes move slowly,
and the skin is getting thicker. The arms and legs may move but not with enough force
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to be felt by the mother.
Week 17
Week 18
Week 19
Week 20
Week 21
Week 22
Week 23
Week 24
Week 25
Week 26
Week 27
Week 28
Week 29
Week 30
Week 31
Week 32

3rd
Trimester

Week 33
Week 34
Week 35
Week 36
Week 37
Week 38
Week 39

Baby's Toenails Develop - The baby's toenails are beginning to form, and the baby is
becoming more active.
Baby Begins to Hear - The baby may now be able to hear sounds, the eyes are
beginning to face forward, and the digestive system is now working.
Baby Develops Protective Coating - The baby is being coated in a greasy, cheese-like
coating called vernix caseosa to protect the baby's delicate skin from abrasions,
chapping, and hardening.
Halfway Point - By now, the mother can feel the baby's movements, the baby is
regularly sleeping and waking, and he or she may even be awakened by loud noises.
Baby Can Suck His or Her Thumb - The baby is covered in fine hair to keep the vernix
caseosa on the surface of the skin. The baby's suckling reflex is developing.
Baby's Hair Becomes Visible - The baby's eyebrows and hair are becoming visible.
Brown fat is also forming as a source of heat.
Fingerprints and Footprints Form - The baby's eye movements become more rapid,
ridges are forming on the baby's hands and feet that will eventually become prints, and
the baby may also begin hiccupping.
Baby's Skin is Wrinkled - The baby's skin becomes wrinkled. The skin is translucent
and may be a pink/red color due to visible blood in the capillaries.
Baby Responds to Others' Voices - The baby may be able to respond to familiar sounds
such as the sound of the mother or father's voice.
Baby's Lungs Develop - The baby's lungs are beginning to produce surfactant, a
substance that allows the air sacs in the lungs to inflate and not stick together once
deflated.
2nd Trimester Ends - The baby's nervous system is continuing to mature. The baby is
also gaining fat, making the skin appear smoother.
Baby's Eyes Partially Open - The baby's eyes can partially open, and his or her
eyelashes have formed. The central nervous system can direct rhythmic breathing
movements and control body temperature.
Baby Kicks and Stretches - The baby can kick, stretch, and make grasping movements.
Baby's Hair Grows - The baby can open his or her eyes wide, the baby may have a
headful of hair at this time, and red blood cells are forming in the baby's bone marrow.
Baby's Rapid Weight Gain Begins - Now that the baby has completed the majority of
his or her development, it is time for the baby to quickly gain weight.
Baby Practices Breathing - The baby begins to lose the fine hair that was clinging to
the protective coating, the baby's toenails may be visible, and the baby begins to
practice breathing.
Baby Detects Light - The baby's pupils may begin changing size when stimulated by
light. The baby's bones are hardening, but the skull remains soft so as to fit through the
birth canal.
Baby's Fingernails Grow - The baby's fingernails have grown so much that they should
reach his or her fingertips.
Baby's Skin is Smooth - The baby's skin continues to smooth out and may appear
chubby.
Baby Takes Up Most of the Amniotic Sac - The space inside the uterus is becoming
cramped for the baby, but the mother should still feel small movements as the baby
wiggles, rolls, and stretches.
Baby Might Turn Head Down - The baby should have a firm grasp. Also, to prepare
for birth, the baby's head may turn down and begin descending into the pelvic cavity.
Baby's Toenails Grow - The baby's toenails now reach the end of his or her toes. The
baby has also shed most of his or her fine hair.
Baby's Chest is Prominent - The baby's chest is becoming more apparent, and he or she
is gaining more fat to maintain heat after birth.
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Mother's Due Date Arrives - The baby should be fully developed and prepared to make
his or her entry any day.
Table 1. The above table shows the weekly gestational fetal development from 2 weeks prior to conception to full
term (Mayo Clinic Staff, 2020).
Week 40

Each progressing week in a fetus’s maturation and growth is very critical and important.
Critical fetal development starts as early as five weeks. At this time, the embryo begins
developing its major system and structures (Fetal Development, 2020). From weeks six to seven,
the embryo begins to form limbs, its brain forms into five separate sections, eyes and ears as well
as tissues that will eventually form bones are developing, and the embryo’s heart begins beating
regularly (Fetal Development, 2020). At week eight, the embryo’s arms, hands, legs, and feet
continue forming and growing; the brain also continues growing, and the lungs begin to form
(Fetal Development, 2020). By week nine, all of the embryo’s major organs have begun growing
(Fetal Development, 2020). At week 10, the baby is no longer considered an embryo, but instead,
is considered a fetus from this moment until birth (Fetal Development, 2020). From weeks 11 to
14, the fetus continues defining its structures (Fetal Development, 2020). Weeks 15 to 18 are
when the fetus begins to move around and stretch in utero (Fetal Development, 2020). This
movement continues and intensities into week 22. During weeks 23 to 25, the fetus begins to
form the lower airways of its lungs (Fetal Development, 2020). During week 26, air sacs in the
lungs begin to form, but the lungs are still not supportive enough to ensure survival without help
(Fetal Development, 2020). During weeks 27 to 30, the fetus’s respiratory system begins to
produce surfactant (Fetal Development, 2020). The Merriam-Webster Dictionary defines
surfactant as “a surface-active substance” (Merriam-Webster, n.d.). Surfactant is indeed a
surface-active substance within the lungs as it helps reduce surface tension at the air-liquid
interface of the alveoli, or air sacs, within the lung to prevent collapsing at the end of exhalation
(Nkadi et al, 2009). During weeks 31 to 34, the fetus’s lungs still are not fully matured (Fetal
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Development, 2020). Between weeks 35 to 37, the fetus’s blood vessels and bones are fully
formed (Fetal Development, 2020). From week 38 until birth, the fetus is considered full term,
fully developed, and due any day (Fetal Development, 2020). While this goes into detail of the
whole developmental process, lung development is not explicitly explained.
Biweekly Lung Development in Utero

Figure 1. The figure above shows the biweekly development of the lungs from conception to full term.

From Figure 1, the timeline of which the lungs develop can better understood. From
about three and a half weeks to 16 weeks, it is clear that the fetus forms major airways, the
bronchial tree, portions of the respiratory parenchyma, and acinus. The parenchyma includes the
gas-exchanging portion (Parenchyma, n.d.). The acinus is the smallest unit of lung tissue and
consists of a terminal bronchiole and the lung parenchyma that will eventually form from it
(Acinus, 2011). This stage includes the embryonic and pseudoglandular periods, and is the
organogenesis portion of lung development. At 16 weeks, the organogenesis portion of lung
development is complete, and the fetus enters into the differentiation portion. From 16 weeks to
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24 weeks, including the termination of the pseudoglandular period and the bulk of the canalicular
stage, the lung periphery is formed, the epithelial cells in the lungs start to differentiate and take
on new jobs, and the air-blood barrier is formed. From 24 weeks to 36 weeks, or the termination
of the canalicular period and the bulk of the saccular period, the air spaces or sacs of the lungs
begin to expand as the fetus practices breathing and the first traces of surfactant are detected.
Surfactant is first detected around 25 weeks and the amounts increase as the fetus progresses
gestationally. Lastly, from 36 weeks to full term or birth, the fetus undergoes the termination of
the saccular period as well as the full alveolar period where secondary septation occurs, meaning
the alveoli in the fetus’s lungs will separate and prepare for breathing air after birth. This is the
completion of the differentiation portion of lung development.
As described earlier, the lungs are still not fully mature even at week 34. What happens
when these babies are born prematurely? How does this premature birth affect further lung
development out of utero and into the early stages of life? How are the lungs artificially matured
in this setting? These are all very relevant and significant questions that contribute to learning
more about gestational lung development and how researchers, doctors, and technologists can
work to overcome and more effectively treat these infants so as to reduce overall time spent in
the NICU. Seeing that surfactant is not detected in amniotic fluid until 25 weeks gestational, it is
not a surprise that if the fetus is delivered around this time, the baby would have a difficult
journey as they are not able to breathe on their own, or at least not efficiently, not only as an
infant but also into their childhood or even adult life. So, what is the current treatment for
premature babies with underdeveloped lungs? Because the lungs are underdeveloped, the babies’
bodies are not able to deliver an adequate amount of oxygen to all of their organs and tissues. To
treat this, it is common for the infant to receive oxygen therapy, or even a ventilator and
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medication (Healthwise Staff, 2017). This treatment allows the premature baby to absorb oxygen
and ultimately breathe (Healthwise Staff, 2017). Medications given to premature babies often
include diuretics or steroids to stimulate lung function, albuterol to aid in symptom relief, etc.
(The Children’s Hospital of Philadelphia, 2014). One of the main issues with premature baby
lungs is the lack of surfactant. Premature baby’s’ lungs are typically treated with surfactant
shortly after birth, and the baby’s’ oxygen-blood saturation levels normally increase almost
immediately or within minutes (Healthwise Staff, 2017). The babies are treated with this
surfactant intratracheally (List of Lung Surfactants, n.d.). Physicians can use several different
types of surfactant. “In the US, artificial surfactant used for surfactant replacement therapy is
extracted from the lung of a cow or a pig” (Mandile, 2018). Curosurf, generically known as
poractant, chemically known as Poractant alfa [BAN], is a type of surfactant extracted from
porcine lungs (Poractant alfa [BAN], n.d.). Infasurf, generically known as calfactant, is a type of
surfactant extracted from bovine lungs (Bloom, B. T., et al, 1997). Survanta, generically known
as beractant, is also extracted from bovine lungs. Surfaxin, generically known as lucinactant, is a
synthetic substitution type of surfactant (Szydlo & Klemm, 2015). Another artificial surfactant is
Exosurf, but it is no longer available (Palca, 2015). All of these different types of artificial
surfactants aim to accomplish the same goal of helping the baby breathe. To accelerate lung
development while in utero, some mothers choose to go through several rounds of corticosteroid
injections resulting in rapidly matured lungs for the fetus (Healthwise Staff, 2017). “In the
presence of preterm premature rupture of the membranes, antenatal corticosteroid therapy
reduces the frequency of respiratory distress syndrome, intraventricular hemorrhage, and
neonatal death, although to a lesser extent than with intact membranes” (Avery, et al, 1994). This
means that in the case of a membrane such as the amniotic sac rupturing prior to full-term
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pregnancy status, these corticosteroids give the baby a better chance of not going into respiratory
distress due to underdeveloped lungs. The mother can also be administered these steroids while
the fetus is still in utero, but the effect on maturing the fetus’s lungs without a ruptured
membrane, like the amniotic sac, is less extensive. Avery, et al goes on to say that “antenatal
corticosteroid therapy is indicated for women at risk of premature delivery with few exceptions
and will result in a substantial decrease in neonatal morbidity and mortality,” (1994). Avery, et al
includes the following legends and table, Table 2, to show the recommendations of each case the
corticosteroids should or should not be administered (1994).
Evidence for Efficacy of Corticosteroids and Strength of Recommendation According to
Delivery Interval, Gestational Age, Status of membranes, and Neonatal Outcome
Quality of
Evidence for
Benefit

Strength of Recommendation

I
I
I

B
A
C

I
I
I

A
A
C

I

B

I
I
I

A
A
A

Interval from Treatment to Delivery
<24 hours
24 hours to 7 days
>7 days
Gestational Age
Delivery at 24-28 weeks
Delivery at 29-34 weeks
Delivery at >34 weeks
Preterm Premature Rupture of
Membranes
Neonatal Outcomes
Mortality
Respiratory distress syndrome
Intraventricular hemorrhage
Table 2 Legend 1: Quality of Evidence
I: Evidence obtained from at least one properly designed randomized controlled trial.
II-1: Evidence obtained from well-designed controlled trials without randomization.
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II-2: Evidence obtained from well-designed cohort or case-control analytic studies, preferably
from more than one center or research group.
II-3: Evidence obtained from multiple time series with or without the intervention. Dramatic
results in uncontrolled experiments (such as the results of the introduction of penicillin treatment
in the 1940's) could also be regarded as this type of evidence.
III: Opinions of respected authorities, based on clinical experience, descriptive studies, or
reports of expert committees.
Table 2 Legend 2: Strength of Recommendation Regarding Corticosteroid Administration
A: There is good evidence to support use.
B: There is fair evidence to support use.
C: There is inadequate evidence to argue for or against use.
D: There is fair evidence to avoid use.
E: There is good evidence to avoid use.
Table 2. The above table and legends reviews the evidence for efficiency and the strength of recommendation to if
corticosteroids should be administered (Avery, et al, 1994).

While studies are still being conducted and this method seems to be safe and effectual to
give to mothers while in utero, it is not encouraged to have a premature infant receive several
rounds of the corticosteroids directly as this has led to several ongoing issues in later years such
as neurological damage, damage and bleeding to the gastrointestinal tract, blood sugar problems,
which may lead to diabetes, and high blood pressure (Healthwise Staff, 2017). Because the
monitoring and testing are so continuous and ongoing, the baby will be placed in an incubator in
the NICU so the staff can keep a close eye on the baby’s vital signs parameters to see that they
are improving. The incubator also keeps the baby warm so they are able to maintain core body
temperature. Once the baby can be held, skin-on-skin contact is commonly practiced for this
same reason. If the baby’s vitals do not improve within a certain amount of time, this could lead
to a number of other issues such as chronic lung disease, or CLD, which is also known as
bronchopulmonary dysplasia, or BPD (The Children’s Hospital of Philadelphia, 2014).
Medications may also be ordered to stimulate the lungs and strengthen breathing (Mayo Clinic
Staff, 2017). In other words, current treatment for underdeveloped lungs in premature babies is
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the administration of surfactant and medication as well as a stay in the NICU to monitor the
babies’ overall health.
NICU Technology: Early Days and Current
How were premature infants treated in the early days, prior to current technologies?
Pierre-Constant Budin was a French obstetrician who had a great impact on the health of
pregnant women and their babies in the early 1900s (Payne, 2016). His career goal was to reduce
infant mortality, and he did so by educating mothers on the importance of breastfeeding; when
breastfeeding was not an option, he advised that sterilized cows milk be used to feed the infants
to reduce infection and the spreading of bad bacteria (Payne, 2016). Budin also brought the term
gavage to life. Gavage is basically feeding tubes that lead directly into the stomach. This
innovation allowed physicians of the time to give proper nutrition to infants who were not able to
eat on their own. Budin was the assistant to another French obstetrician, Etienne Stephane
Tarnier (Payne, 2016). Tarnier recognized the need for incubators to keep the premature infants
warm and allow them to grow and gain weight so he came up with the best solution he could
given the era and the resources he had available. He came up with a wooden box with a glass lid
and a hot water bottle inside (Payne, 2016). This innovation contributed to a 28 percent decrease
in infant mortality within three years at the hospital where Dr. Tarnier worked (Payne, 2016).
During this time, these special incubators were not accepted in hospitals due to its crude
appearance (Payne, 2016). To encourage the incubator’s popularity since it had such great
potential for aiding premature babies, a student of Budin, Martin Couney, came up with an
unconventional way to spread the word. In efforts to increase incubator popularity, Dr. Couney
provided this treatment to infants free of charge (Payne, 2016). He would take these infants to
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local fairs and shows where he would charge onlookers 25 cents a piece to see the babies who
were being kept alive by this new innovation to pay for the babies’ treatments (Payne, 2016).
This practice, while unconventional, did its job of spreading the word because shortly
after Dr. Couney died in 1950, American hospitals began allowing the use of incubators for the
care of premature babies (Payne, 2016). “It was not until after World War II that hospitals began
to create Special Care Baby Units, the precursors to modern NICUs,” (Payne, 2016). Special
Care Units for infants became a staple when doctors began to realize that “heat, humidity, and a
steady supply of oxygen” lead to an increase in survival rate among infants (Payne, 2016).
Initially, hospitals were hesitant to implement incubators due to the expense, restricted access,
and lack of confirmation of its effectiveness, but the decreased mortality rate was too obvious to
ignore. The original incubator was later amended and improved by Dr. Julian Hess at Reese
Hospital in Chicago, Illinois when he not only was able to regulate heat and humidity, but also
administer oxygen to the infants (Payne, 2016). “The following decade, incubators with clear
plastic walls were introduced, allowing doctors and nurses to easily see and access the babies,”
(Payne, 2016).
Dr. Louis Gluck discovered that washing babies regularly lead to a decrease in infection
among these infants; regardless of how clean the babies were, one of the biggest issues in
spreading bacteria and infection among these infants was getting the staff and visitors to wash
their hands before handling the children (Payne, 2016). “To this day, this remains one of the
biggest threats in the NICU,” (Payne, 2016). Gluck eventually redesigned the Special Care
Nursery to have all the incubators in one room instead of sectioned off so it was easier for the
doctors and nurses to easily access and manage the care of each infant (Payne, 2016). Gluck was
also instrumental in the design of the L/S ratio test (also known as the Lecithin-Sphingomyelin
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ratio), which determines the maturity of infant’s lungs (Payne, 2016). This, in turn, provides
indications of infant’s chances of developing certain respiratory diseases. Because of these
accomplishments, Gluck is often hailed as the father of neonatology (Payne, 2016).
Until the 1970s, most of the emphasis was placed on devices, and family involvement
was not much of a thought. In the 1970s, however, this all began to change (Payne, 2016). “The
Newborn Individualized Developmental Care and Assessment Program was developed by
Heidelise Als, which encouraged family involvement and individualized plans for each baby,”
(Payne, 2016). Once the program began, doctors learned family involvement dwindled down the
amount of days the babies required ventilators (Payne, 2016). “Kangaroo care,” or skin-to-skin
contact became a very significant aspect in the babies’ health due to the importance of the
parent-child bond that aids in “bonding, stabilize the baby’s breathing, heart rate and body
temperature, and help the baby gain weight and grow,” (Payne, 2016). Because of the bonding
and how well the babies were responding, many hospitals initiated visiting hours so the families
of the infant could come in and bond with them (Payne, 2016).
In the 1990s, as technology became more readily available, affordable, and
understandable, the care for more high-risk babies became more attainable; babies born as early
as 23 weeks gestational, and weighing as little as one pound were being able to be saved (Payne,
2016). As of earlier this year, survival rates are typically as following:
Average Likelihood of Infant Survival by Gestational Age
Gestational Age
22 weeks
23 weeks
24 weeks
25 weeks
26 weeks
27 weeks

Likelihood of Survival
0%
17%
39%
50%
80%
90%
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90-95%
95%
95-100%

Table 3. The above table indicates the chances of infant survival based on what gestational age they are born
(Danielsson, 2020).

While this is fairly accurate, there are a couple of babies who may experience a miracle. For
example, in Decatur, Georgia, on December 20, 2019, the youngest surviving premature baby
was born at 21 weeks, 0 days gestational (Bilger, 2020). There are also a number of babies being
born at 22 weeks gestational that are surviving. While it is still questionable how the children
will do long term, they are currently living and thriving.
Technology has since improved and is continuously improving and also improving
neonatal care. A NICU has a lot of equipment they use on a daily basis. A few machines used
daily by staff on NICU babies include, but are not limited to heart or cardiorespiratory monitors,
blood pressure monitors, thermometers, pulse oximeters, portable x-ray machines, CT scanners,
MRI machines, endotracheal tubes (ET), respirators or mechanical ventilators, continuous
positive airway pressure (CPAP) machines, and extracorporeal membrane oxygenation (ECMO)
machines (Stanford Children’s Health Staff, n.d.). All of these technologies, along with
technologies that are currently being developed, can help further decrease premature infant
mortality rate.
Significance
Why does this research need to be done? What is wrong with the current way things are
being done? Babies are still being successfully saved as young as 21 and 22 weeks gestational.
How will additional research better or advance the process of lung development in a quicker,
more effective way? Will focusing solely on rapid lung development in utero be enough to deem
more at risk babies viable and savable? How long will developing a new technology take? How
much will research, design, and manufacturing cost? Is the healthcare system willing to do
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experimental trials on pregnant women and their babies? These are all relevant questions that are
currently up in the air as research is being done to look for answers to solve this issue of losing
premature babies in hopes to decrease infant mortality rate.
This research needs to be done to save more premature lives and decrease mortality rates.
While the current way things are being done, using surfactant as well as medication to stabilize
and aid the infant before they can breathe on their own, is efficient, there is always room for
improvement. Researchers and healthcare workers need to be looking at how the lungs are
developed in utero and the process and stages the respiratory system goes through in order to
stabilize the lungs to a point where they can operate on their own at an earlier gestational age.
Once this process is known and understood, research can be done to look into treating all fetuses
while still in utero as a precautionary measure in case the fetus was to be born before they reach
full-term. By designing and researching new, innovative ideas to aid in enhancing surfactant
production levels while still in utero, the amount of lung related complications the premature
infant might encounter can hopefully be eliminated, or at least minimized. This may also prove
to decrease the premature mortality rate alongside finding new, creative ideas, as the main goal is
to save as many lives as possible. If jumpstarting lung development in utero is not attainable, is
there possibly a way to preserve the fetus outside the amniotic sac to allow the baby to fully
develop without all of the complications? Whatever the future holds, not only will babies be
saved, but this will also be saving parents from heartache and a long recovery road. Bringing a
baby into the world should remain beautiful and intimate, instead of turning the mood into a
gloomy, possibly worst day of your life moment.
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Methods
How was this research conducted? The research done for this study really dove in to see
what research had already been done, what ideas had been successful, and which have failed. Is
there anything that past researchers have overlooked or missed? It studied what technology and
medication were part of the current protocols, and while they work, research suggests the process
could be sped up and be more effective. The research focused in on new and upcoming
technologies that are still under development in order to more proficiently treat the stilldeveloping lungs of premature babies. It looked at studies done to boost surfactant stimulation
and secretion earlier than the normal 25 to 30 weeks gestational. It also looked at studies done
after birth to boost the infant’s respiratory system in a quicker manner than the current practice
of supplying the infant with surfactant while the infant stays in an incubator in the NICU until
they are considered to have strong enough lungs to be able to breathe independently. This
research lastly looked at ways to preserve the fetus if it is born prematurely so they are able to
continue developing as if they were still in the amniotic sac in the mother’s uterus. The main
goal of this study is to provide faster, successful care to premature infants born with
underdeveloped lungs still needing aid to save the baby’s life and decrease infant mortality at the
time of birth.
Discussion
The main causes of mortality in premature infants revolve around issues with the heart
and lungs. Drugs have been created to aid the mother in stopping preterm labor, but these drugs
do not always work. What happens if the baby is still born prematurely? How much is really
known about fetal development, and how can researchers learn more about, not just the fetal
development timeline but also the processes in which each phase of development occurs? Can
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these processes be manipulated and the order of development be switched up? So far, this study
has looked at what has been done in the past as well as current protocols, but can be done to
better address the issue at hand? Research needs to be done to brainstorm new ideas that will aid
in saving premature babies born way before term. Ideas may regard the baby while still in utero
or after birth. One idea that needs to be tested is surfactant supplements for the mother to take
while the baby is still in utero. Similar to the prenatal vitamins that pregnant women take to
provide extra nourishment for themselves and the fetus, this type of supplement would target the
fetus’s lung developmental process and jumpstart the production of surfactant for the fetus
before natural surfactant is produced around 25 weeks gestational. Another idea would be to
administer surfactant to the fetus directly or add it to the amniotic fluid. Both of these ideas, if
successful, would be a precautionary measure just in case the mother would happen to go into
preterm labor. There is also current research being done regarding placing the baby in an
artificial sac resembling the amniotic sac. The baby would stay in this sac until it was considered
full-term. Then, the sac would be broken, and the baby’s developmental progression would be
assessed to determine further action. Overall, the healthcare system, physicians, and researchers
are always looking for new advancements and technologies that are going to benefit billions of
mothers, babies, and families all over the world.
A study that would need to be performed would be to evaluate what impact artificial
surfactant supplements ingested by the mother might have on the fetus. What does surfactant
actually consist of? “Lung surfactant is a complex with a unique phospholipid and protein
composition,” (Bernhard, 2016). The article goes on to say, “Surfactant comprises 80%
phosphatidylcholine (PC), of which dipalmitoyl-PC, palmitoyl-myristoyl-PC and palmitoylpalmitoleoyl-PC together are 75%. Anionic phosphatidylglycerol and cholesterol are about 10%
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each, whereas surfactant proteins SP-A to -D comprise 2-5%,” (Bernhard, 2016). Surfactant is
“secreted by type II alveolar cells into the alveolar epithelial lining,” (Chaiworapongsa, Hong,
Hull, Romero, & Whitsett, 2008). While antenatal corticosteroids are administered to mothers at
risk of pre-term labor between 23 and 26 weeks gestational to hasten fetal lung development
between 28 to 34 weeks, there is no evidence to suggest that the steroids increase fetal lung
development if administered prior to 23 weeks gestational (Wapner, 2013). The steroids are used
to speed up the secretion of natural surfactant in the fetus, but if artificial surfactant is
administered to the mother prior to 23 weeks, either independently or coupled with the antenatal
corticosteroid, would this better prepare the fetus if it were to be born prematurely? Would the
fetus even be far enough along in its lung developmental process for this to be beneficial? If the
lungs are not sufficiently developed enough prior to 23 weeks for this to be beneficial, is there a
way to stimulate lung development week-by week or even stage-by-stage, for example,
embryonic, pseudoglandular, and canalicular? No studies are currently being conducted to
answer these questions, but, in theory, it seems like it would be something that may provide
favorable outcomes for the infant. If successful, this could be administered only to women who
are at risk of going into pre-term labor or to every pregnant woman as a preventative measure.
In addition to the previous idea, another study that needs to be further investigated is
injecting artificial surfactant into the amniotic sac in the mother’s womb as a precaution in case
the mother was to go into pre-term labor. The surfactant would be injected near the fetus’s mouth
and nostrils so as to enter the fetus’s “airways” before it’s birth (Abdel-Latif, Osborn, Challis,
2010). Preliminary animal and human studies have been conducted and deemed successful;
however, no high-quality studies have since been conducted (Abdel-Latif, Osborn, Challis,
2010). Studies have been conducted to conclude that intra-amniotic instillation reduces
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respiratory distress syndrome, or RDS, among women who are 28 to 34 weeks pregnant, but
studies on women who are earlier than 28 weeks have not been performed (Agarwal, Bathwal,
Kriplani, Deorari, & Bhatla, 2016). As before, if this is tested and tried, initially, researchers
need to know if the fetus’s lungs are even capable of using surfactant before it is naturally made.
If not, to reiterate, researchers could look into ways to stimulate lung development either weekby-week or stage-by-stage. Anything that can be done to rapidly develop fetal lungs will increase
the fetus’s chances of survival out of the womb.
One technological innovation that is still being studied and explored is an artificial
womb, commonly referred to as a biobag (Adereyko, 2020). In theory, once the fetus is born
prematurely, the baby would be placed in an artificial sac resembling the amniotic sac where the
infant would be able to continue with the development until the sac is broken at, what would be
considered, full-term (Regis College, 2020). The artificial amniotic fluid is continuously
exchanged as to maintain and preserve the fluid filled lungs (Partridge, Davey, Hornick, et al,
2017). In 2017, Erika Engelhaupt wrote an article stating, “eight fetal lambs survived and grew
inside an artificial womb for four weeks, the longest an animal has done so” (Engelhaupt, 2017).
While the lamb was in the artificial womb, its organs, including the lungs, developed just as if it
was in the mother’s womb (Engelhaupt, 2017). The lambs grew into adulthood seemingly having
no problems and have had normal development since birth (Engelhaupt, 2017). It is hard to gain
a grasp on their mental state as there is no “intelligence test” for lambs, and this is concerning as
researchers still question the effectiveness as they cannot understand how a human fetus would
react (Engelhaupt, 2017). Even without knowing the mental drawbacks this method might have
on human fetuses, the idea of placing a fetus in an artificial womb so it can develop normally up
until full-term status is definitely something physicians should be able to get behind for the
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benefit of the child. The article goes on to say, “If the new device succeeds, the parents of a
premature baby might someday peer into an incubator that looks a bit like an aquarium”
(Engelhaupt, 2017). The baby would be placed in a clear, large bag filled with artificial amniotic
fluid; the baby would “breathe” the artificial amniotic fluid just as they would in the mother’s
womb, and the umbilical cord would be hooked up to a machine that would supply oxygen and
eradicate carbon dioxide (Engelhaupt, 2017). The main goal of the artificial womb, however, is
not to “extend the limits of viability,” but to “improve survival for extremely premature infants”
(Engelhaupt, 2017). The fetus would be “delivered” from the artificial womb at about 28 weeks
of typical gestation to lessen the risk of infection (Engelhaupt, 2017). The lungs would be
developed sufficiently to breathe on their own at this point as well (Engelhaupt, 2017). More
testing is still being done on animal subjects before researchers can move on to human testing,
but researchers are hopeful to begin testing on humans in the next three to five years
(Engelhaupt, 2017). A disadvantage of this method would be cardiac failure due to added stress
on the fetus’s heart due to the umbilical oxygen/carbon dioxide pump (Partridge, Davey,
Hornick, et al, 2017). While this method would not necessarily cut down on overall time in the
NICU, it would give the infant a better chance at proper development as well as not having any
physical or mental deficits later on in life, such as cerebral palsy.
Conclusion
In summary, the goal is to save the lives of as many premature infants as possible. In
addition, not only will these new innovation have the ability to save these babies’ lives, but these
innovations will also be guarding the babies’ parents from the heartache of losing a child. This
study looked into several different alternatives to the current practice of treating premature
infants. It specifically investigated the surfactant supplements for the mother to take while still
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pregnant with the fetus, either independently or paired with antenatal corticosteroids.
Additionally, the study assessed intra-amniotic instillation before 28 weeks gestational. Lastly,
this study examined the artificial sac, or biobag, for premature babies to go into at the time of
premature birth to simulate the environment of still being in the uterus so they could develop
until they are considered full-term. Each of these ideas and innovations involve either rapidly
developing fetal lungs or allowing the fetal lungs to mature at a normal pace, just outside the
mother’s body. They each have the goal of giving the baby the best chances of survival outside
the womb. In conclusion, all lives matter and deserve the best chance at life, even the lives of
babies that have not even entered the world yet. In doing this research, several ideas have been
found that warrant further research that may eventually surpass the current practices in
neonatology and save additional lives worldwide.
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